AbbVie to Host First-Quarter 2025 Earnings Conference Call

3/31/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ABBV alert in real time by email

NORTH CHICAGO, Ill., March 31, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its first-quarter 2025 financial results on Friday, April 25, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.

Media:	Investors:
Gabby Tarbert	Liz Shea
(224) 244-0111	(847) 935-2211
[email protected]	[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-host-first-quarter-2025-earnings-conference-call-302414655.html

SOURCE AbbVie

Get the next $ABBV alert in real time by email

Date	Price Target	Rating	Analyst
5/14/2025	$205.00	Buy → Neutral	Citigroup
4/22/2025	$210.00	Overweight	Cantor Fitzgerald
12/10/2024	$191.00	Neutral	BofA Securities
12/5/2024	$180.00	Outperform → Neutral	Daiwa Securities
11/22/2024	$206.00	Market Perform → Outperform	Leerink Partners
11/15/2024	$205.00	Outperform	Wolfe Research
11/4/2024		Hold → Buy	Argus
10/17/2024	$203.00	Mkt Perform	Bernstein

AbbVie to Host First-Quarter 2025 Earnings Conference Call

Chat with this insight

Recent Analyst Ratings for
$ABBV

$ABBV
SEC Filings

SEC Form 11-K filed by AbbVie Inc.

SEC Form SD filed by AbbVie Inc.

SEC Form 10-Q filed by AbbVie Inc.

$ABBV
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Falk Thomas J was granted 1,203 shares (SEC Form 4)

Director Freyman Thomas C was granted 1,203 shares, increasing direct ownership by 0.96% to 126,751 units (SEC Form 4)

Director Tilton Glenn F was granted 1,203 shares, increasing direct ownership by 2% to 51,564 units (SEC Form 4)

$ABBV
Press Releases

Fastest customizable press release news feed in the world

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

$ABBV
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AbbVie downgraded by Citigroup with a new price target

Cantor Fitzgerald initiated coverage on AbbVie with a new price target

BofA Securities resumed coverage on AbbVie with a new price target

AbbVie to Host First-Quarter 2025 Earnings Conference Call

Chat with this insight

Recent Analyst Ratings for $ABBV

$ABBV SEC Filings

SEC Form 11-K filed by AbbVie Inc.

SEC Form SD filed by AbbVie Inc.

SEC Form 10-Q filed by AbbVie Inc.

$ABBV Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Falk Thomas J was granted 1,203 shares (SEC Form 4)

Director Freyman Thomas C was granted 1,203 shares, increasing direct ownership by 0.96% to 126,751 units (SEC Form 4)

Director Tilton Glenn F was granted 1,203 shares, increasing direct ownership by 2% to 51,564 units (SEC Form 4)

$ABBV Press Releases

Fastest customizable press release news feed in the world

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes

U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

$ABBV Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

AbbVie downgraded by Citigroup with a new price target

Cantor Fitzgerald initiated coverage on AbbVie with a new price target

BofA Securities resumed coverage on AbbVie with a new price target

Recent Analyst Ratings for
$ABBV

$ABBV
SEC Filings

$ABBV
Insider Trading

$ABBV
Press Releases

$ABBV
Analyst Ratings